$JAZZ
Jazz Pharmaceuticals PLC

2021 Q1 Form 10-Q Financial Statement

#000123252421000031 Filed on May 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q4 2020 Q1
Revenue $607.6M $665.5M $534.7M
YoY Change 13.62% 14.4% 5.22%
Cost Of Revenue $40.20M $50.20M $28.70M
YoY Change 40.07% 42.21% -14.33%
Gross Profit $567.4M $611.1M $501.5M
YoY Change 13.13% 12.93% 6.75%
Gross Profit Margin 93.39% 91.83% 93.8%
Selling, General & Admin $260.5M $247.2M $208.4M
YoY Change 25.0% 15.35% 24.09%
% of Gross Profit 45.91% 40.45% 41.55%
Research & Development $76.57M $127.7M $86.11M
YoY Change -11.07% 31.11% 43.26%
% of Gross Profit 13.5% 20.9% 17.17%
Depreciation & Amortization $4.779M $71.70M $4.527M
YoY Change 5.57% -59.7% 27.92%
% of Gross Profit 0.84% 11.73% 0.9%
Operating Expenses $337.1M $441.9M $294.5M
YoY Change 14.46% -8.92% 29.14%
Operating Profit $162.1M $169.2M -$189.7M
YoY Change -185.47% 202.34% -241.82%
Interest Expense -$27.38M -$28.60M -$18.50M
YoY Change 48.01% 39.51% 3.2%
% of Operating Profit -16.89% -16.9%
Other Income/Expense, Net
YoY Change
Pretax Income $135.7M $144.8M -$209.3M
YoY Change -164.83% 254.9% -281.67%
Income Tax $18.00M $10.80M -$51.30M
% Of Pretax Income 13.27% 7.46%
Net Earnings $121.8M $133.4M -$157.8M
YoY Change -177.19% 80.31% -285.25%
Net Earnings / Revenue 20.05% 20.05% -29.52%
Basic Earnings Per Share $2.16 $2.39 -$2.82
Diluted Earnings Per Share $2.09 $2.33 -$2.82
COMMON SHARES
Basic Shares Outstanding 56.47M shares 55.71M shares 55.96M shares
Diluted Shares Outstanding 58.39M shares 55.96M shares

Balance Sheet

Concept 2021 Q1 2020 Q4 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.433B $2.133B $981.6M
YoY Change 147.81% 97.98% 17.91%
Cash & Equivalents $2.098B $1.058B $701.6M
Short-Term Investments $1.581B $1.616B $755.3M
Other Short-Term Assets $147.7M $152.5M $94.30M
YoY Change 56.66% 93.28% 49.72%
Inventory $115.5M $95.40M $85.61M
Prepaid Expenses $57.19M $62.42M $38.82M
Receivables $414.0M $396.5M $317.3M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $3.167B $2.840B $1.518B
YoY Change 108.67% 74.18% 16.24%
LONG-TERM ASSETS
Property, Plant & Equipment $123.9M $127.9M $129.6M
YoY Change -4.4% -2.72% 23.44%
Goodwill $938.4M $958.3M $909.2M
YoY Change 3.21% 4.16% -1.17%
Intangibles $2.108B $2.195B $2.239B
YoY Change -5.83% -10.07% -16.45%
Long-Term Investments
YoY Change
Other Assets $30.35M $25.72M $47.11M
YoY Change -35.57% -46.32% 15.64%
Total Long-Term Assets $3.590B $3.696B $3.698B
YoY Change -2.92% -5.43% -6.97%
TOTAL ASSETS
Total Short-Term Assets $3.167B $2.840B $1.518B
Total Long-Term Assets $3.590B $3.696B $3.698B
Total Assets $6.756B $6.536B $5.215B
YoY Change 29.55% 18.0% -1.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $77.74M $26.95M $66.31M
YoY Change 17.24% -41.08% 55.4%
Accrued Expenses $374.0M $352.7M $261.0M
YoY Change 43.29% 30.79% -4.4%
Deferred Revenue $2.373M $2.546M $4.176M
YoY Change -43.18% -46.06% -11.53%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $248.6M $246.3M $33.39M
YoY Change 644.64% 637.78% 0.0%
Total Short-Term Liabilities $752.1M $653.7M $396.1M
YoY Change 89.86% 79.36% -4.32%
LONG-TERM LIABILITIES
Long-Term Debt $1.853B $1.849B $1.577B
YoY Change 17.5% 17.45% 0.75%
Other Long-Term Liabilities $105.9M $101.1M $117.3M
YoY Change -9.71% -7.52% 11.39%
Total Long-Term Liabilities $1.959B $1.950B $1.694B
YoY Change 15.62% 15.83% 1.42%
TOTAL LIABILITIES
Total Short-Term Liabilities $752.1M $653.7M $396.1M
Total Long-Term Liabilities $1.959B $1.950B $1.694B
Total Liabilities $2.711B $2.603B $2.090B
YoY Change 29.69% 27.14% 0.28%
SHAREHOLDERS EQUITY
Retained Earnings $1.282B $1.160B $770.9M
YoY Change 66.26% 8.62% -8.86%
Common Stock $2.695B $2.634B $2.294B
YoY Change 17.45% 16.22% 7.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.798B $3.660B $2.809B
YoY Change
Total Liabilities & Shareholders Equity $6.756B $6.536B $5.215B
YoY Change 29.55% 18.0% -1.23%

Cashflow Statement

Concept 2021 Q1 2020 Q4 2020 Q1
OPERATING ACTIVITIES
Net Income $121.8M $133.4M -$157.8M
YoY Change -177.19% 80.31% -285.25%
Depreciation, Depletion And Amortization $4.779M $71.70M $4.527M
YoY Change 5.57% -59.7% 27.92%
Cash From Operating Activities $285.0M $186.2M $273.0M
YoY Change 4.41% 112.07% 34.96%
INVESTING ACTIVITIES
Capital Expenditures $2.168M -$40.20M $4.830M
YoY Change -55.11% 466.2% -39.23%
Acquisitions
YoY Change
Other Investing Activities $739.3M $113.4M $160.0M
YoY Change 362.06% -174.61% -30.43%
Cash From Investing Activities $737.1M $73.20M -$60.08M
YoY Change -1326.92% -146.01% -136.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $139.1M
YoY Change -100.0% 24.99%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $18.28M 55.90M -$147.7M
YoY Change -112.38% -163.74% 13.3%
NET CHANGE
Cash From Operating Activities $285.0M 186.2M $273.0M
Cash From Investing Activities $737.1M 73.20M -$60.08M
Cash From Financing Activities $18.28M 55.90M -$147.7M
Net Change In Cash $1.040B 315.3M $64.26M
YoY Change 1518.11% -298.3% -72.98%
FREE CASH FLOW
Cash From Operating Activities $285.0M $186.2M $273.0M
Capital Expenditures $2.168M -$40.20M $4.830M
Free Cash Flow $282.8M $226.4M $268.1M
YoY Change 5.48% 138.57% 38.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001232524
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
Jazz Pharmaceuticals plc
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
CY2021Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-33500
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
L2
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1032470
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
Fifth Floor, Waterloo Exchange,
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Waterloo Road
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Dublin 4
CY2021Q1 dei Entity Address Country
EntityAddressCountry
IE
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
D04 E5W7
CY2021Q1 dei Country Region
CountryRegion
353
CY2021Q1 dei City Area Code
CityAreaCode
1
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
634-7800
CY2021Q1 dei Security12b Title
Security12bTitle
Ordinary shares, nominal value $0.0001 per share
CY2021Q1 dei Trading Symbol
TradingSymbol
JAZZ
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
56895944 shares
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2097533000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1057769000 USD
CY2021Q1 us-gaap Investments
Investments
335000000 USD
CY2020Q4 us-gaap Investments
Investments
1075000000 USD
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
413976000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
396490000 USD
CY2021Q1 us-gaap Inventory Net
InventoryNet
115475000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
95396000 USD
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
57185000 USD
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
62422000 USD
CY2021Q1 us-gaap Other Assets Current
OtherAssetsCurrent
147727000 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
152491000 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
3166896000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
2839568000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
123863000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
127935000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
125738000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
129169000 USD
CY2021Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2108046000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2195051000 USD
CY2021Q1 us-gaap Goodwill
Goodwill
938398000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
958303000 USD
CY2021Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
258454000 USD
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
254916000 USD
CY2021Q1 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
4724000 USD
CY2020Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
5238000 USD
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
30351000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
25721000 USD
CY2021Q1 us-gaap Assets
Assets
6756470000 USD
CY2020Q4 us-gaap Assets
Assets
6535901000 USD
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
77738000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
26945000 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
374035000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
352732000 USD
CY2021Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
248613000 USD
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
246322000 USD
CY2021Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
49334000 USD
CY2020Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
25200000 USD
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2373000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2546000 USD
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
752093000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
653745000 USD
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1852000 USD
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2315000 USD
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1853033000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1848516000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
136020000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
140035000 USD
CY2021Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
109915000 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
130397000 USD
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
105868000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
101148000 USD
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
6000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
6000 USD
CY2021Q1 jazz Nonvoting Euro Deferred Shares
NonvotingEuroDeferredShares
55000 USD
CY2020Q4 jazz Nonvoting Euro Deferred Shares
NonvotingEuroDeferredShares
55000 USD
CY2021Q1 jazz Capital Redemption Reserve
CapitalRedemptionReserve
472000 USD
CY2020Q4 jazz Capital Redemption Reserve
CapitalRedemptionReserve
472000 USD
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2694858000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2633670000 USD
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-179428000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-134352000 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1281726000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1159894000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
3797689000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
3659745000 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6756470000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6535901000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
607581000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
534726000 USD
CY2021Q1 jazz Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment
CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment
40189000 USD
CY2020Q1 jazz Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment
CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment
28657000 USD
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
260508000 USD
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
208400000 USD
CY2021Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
76573000 USD
CY2020Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
86107000 USD
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
68192000 USD
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
62847000 USD
CY2021Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
0 USD
CY2020Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
202250000 USD
CY2021Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2020Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
136139000 USD
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
445462000 USD
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
724400000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
162119000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-189674000 USD
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-27376000 USD
CY2020Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-18496000 USD
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
943000 USD
CY2020Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1132000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
135686000 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-209302000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
18019000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-51287000 USD
CY2021Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
4165000 USD
CY2020Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
182000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
121832000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-157833000 USD
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.16
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.82
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.09
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.82
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56468000 shares
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55956000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58393000 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55956000 shares
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
121832000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-157833000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-46220000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-29990000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
163000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
-579000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
1144000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-4053000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-45076000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-34043000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
76756000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-191876000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
3659745000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
50407000 USD
CY2021Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
23784000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34565000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-45076000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
121832000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
3797689000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3110981000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13264000 USD
CY2020Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
13547000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28731000 USD
CY2020Q1 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
139053000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-34043000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-157833000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
2808500000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
121832000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-157833000 USD
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
68192000 USD
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
62847000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
34485000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
28654000 USD
CY2021Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2020Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
136139000 USD
CY2021Q1 us-gaap Depreciation
Depreciation
4779000 USD
CY2020Q1 us-gaap Depreciation
Depreciation
4527000 USD
CY2021Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
0 USD
CY2020Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
202250000 USD
CY2021Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-19110000 USD
CY2020Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-63976000 USD
CY2021Q1 jazz Provision For Losses On Accounts Receivable And Inventory
ProvisionForLossesOnAccountsReceivableAndInventory
1083000 USD
CY2020Q1 jazz Provision For Losses On Accounts Receivable And Inventory
ProvisionForLossesOnAccountsReceivableAndInventory
2620000 USD
CY2021Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
15688000 USD
CY2020Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
12000000 USD
CY2021Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-7766000 USD
CY2020Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1793000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
18245000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-37861000 USD
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
22014000 USD
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
10235000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2897000 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
17843000 USD
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-157000 USD
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-505000 USD
CY2021Q1 jazz Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-3690000 USD
CY2020Q1 jazz Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-3195000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
51292000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
19604000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
13719000 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-12198000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
24625000 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
20829000 USD
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-637000 USD
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1180000 USD
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
4774000 USD
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
7316000 USD
CY2021Q1 jazz Increase Decrease In Operating Lease Liabilities Noncurrent
IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent
-4182000 USD
CY2020Q1 jazz Increase Decrease In Operating Lease Liabilities Noncurrent
IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent
-3906000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
284997000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
272969000 USD
CY2021Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
760000000 USD
CY2020Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
345000000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2168000 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4830000 USD
CY2021Q1 jazz Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination
PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination
0 USD
CY2020Q1 jazz Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination
PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination
202250000 USD
CY2021Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
CY2020Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
13000000 USD
CY2021Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
20700000 USD
CY2020Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
185000000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
737132000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-60080000 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
50407000 USD
CY2020Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
13264000 USD
CY2021Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
23784000 USD
CY2020Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
13547000 USD
CY2021Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
8347000 USD
CY2020Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
8347000 USD
CY2021Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
CY2020Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
139053000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18276000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-147683000 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-641000 USD
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-948000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1039764000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
64258000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1057769000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
637344000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2097533000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
701602000 USD
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:14pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</span></div>
CY2021Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:14pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and investments to the extent recorded on the balance sheet.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes. As of March 31, 2021, we had foreign exchange forward contracts with notional amounts totaling $425.1 million. As of March 31, 2021, the outstanding foreign exchange forward contracts had a net liability fair value of $10.7 million. As of March 31, 2021, we had interest rate swap contracts with notional amounts totaling $300.0 million. These outstanding interest rate swap contracts had a net liability fair value of $1.5 million as of March 31, 2021. The counterparties to these contracts are large multinational commercial banks, and we believe the risk of nonperformance is not significant.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the U.S., and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and as of March 31, 2021 and December 31, 2020, allowances on receivables were not material. As of March 31, 2021, two customers accounted for 81% of gross accounts receivable, Express Scripts Specialty Distribution Services, Inc. and its affiliates, or ESSDS, which accounted for 67% of gross accounts receivable, and McKesson Corporation and affiliates, or McKesson, which accounted for 14% of gross accounts receivable. As of December 31, 2020, two customers accounted for 80% of gross accounts receivable, ESSDS, which accounted for 68% of gross accounts receivable, and McKesson, which accounted for 12% of gross accounts receivable. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on single source suppliers for most of our products, product candidates and their active pharmaceutical ingredients, or APIs. With respect to Xyrem, the API is manufactured for us by a single source supplier and the finished product is manufactured both by us in our facility in Athlone, Ireland and by our U.S.-based Xyrem supplier.</span></div>
CY2021Q1 jazz Price Per Share To Be Paid To Former Shareholders Cash
PricePerShareToBePaidToFormerShareholdersCash
16.66
CY2021Q1 jazz Exchange Ratio Middle Threshold Numerator
ExchangeRatioMiddleThresholdNumerator
1.66 USD
CY2021Q1 jazz Exchange Ratio Lower Threshold
ExchangeRatioLowerThreshold
0.011929
CY2021Q1 jazz Exchange Ratio Upper Threshold
ExchangeRatioUpperThreshold
0.009760
CY2021Q1 jazz Number Of Shares Per Gw American Depository Share
NumberOfSharesPerGWAmericanDepositoryShare
12 shares
CY2021Q1 jazz Proceeds Multiplier For Cash And Share Amounts
ProceedsMultiplierForCashAndShareAmounts
12
CY2021Q1 jazz Tender Offer Per Share Amount Cash
TenderOfferPerShareAmountCash
200.00
CY2021Q1 jazz Tender Offer Per Share Amount Stock
TenderOfferPerShareAmountStock
20.00
CY2021Q1 jazz Tender Offer Payment To Acquire Business Gross
TenderOfferPaymentToAcquireBusinessGross
7200000000 USD
CY2021Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
2432533000 USD
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
2432533000 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2097533000 USD
CY2021Q1 us-gaap Investments
Investments
335000000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
2132769000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
2132769000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1057769000 USD
CY2020Q4 us-gaap Investments
Investments
1075000000 USD
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1200000 USD
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
4400000 USD
CY2021Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
4500000 USD
CY2021Q1 us-gaap Derivative Asset Fair Value Gross Asset Including Not Subject To Master Netting Arrangement
DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
488000 USD
CY2021Q1 us-gaap Derivative Liability Fair Value Gross Liability Including Not Subject To Master Netting Arrangement
DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
12676000 USD
CY2020Q4 us-gaap Derivative Asset Fair Value Gross Asset Including Not Subject To Master Netting Arrangement
DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
11907000 USD
CY2020Q4 us-gaap Derivative Liability Fair Value Gross Liability Including Not Subject To Master Netting Arrangement
DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
3625000 USD
CY2021Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
23415000 USD
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
16003000 USD
CY2021Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
52117000 USD
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
45758000 USD
CY2021Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
39943000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
33635000 USD
CY2021Q1 us-gaap Inventory Net
InventoryNet
115475000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
95396000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
958303000 USD
CY2021Q1 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-19905000 USD
CY2021Q1 us-gaap Goodwill
Goodwill
938398000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3341902000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1233856000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2108046000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3395214000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1200163000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2195051000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
152570000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
172486000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
172486000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
172486000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
172486000 USD
CY2021Q1 jazz Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
1265532000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2108046000 USD
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
193852000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
195523000 USD
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
69989000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
67588000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
123863000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
127935000 USD
CY2021Q1 jazz Accrued Rebates And Other Sales Deductions
AccruedRebatesAndOtherSalesDeductions
137337000 USD
CY2020Q4 jazz Accrued Rebates And Other Sales Deductions
AccruedRebatesAndOtherSalesDeductions
127534000 USD
CY2021Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
81155000 USD
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
102601000 USD
CY2021Q1 jazz Sales Return Reserve
SalesReturnReserve
20278000 USD
CY2020Q4 jazz Sales Return Reserve
SalesReturnReserve
18368000 USD
CY2021Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
17824000 USD
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
15230000 USD
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
14201000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6660000 USD
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
14048000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
14457000 USD
CY2021Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
12676000 USD
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3625000 USD
CY2021Q1 jazz Accrued Inventory Related Liabilities
AccruedInventoryRelatedLiabilities
11199000 USD
CY2020Q4 jazz Accrued Inventory Related Liabilities
AccruedInventoryRelatedLiabilities
9809000 USD
CY2021Q1 jazz Accrued Clinical Trial Liability
AccruedClinicalTrialLiability
10722000 USD
CY2020Q4 jazz Accrued Clinical Trial Liability
AccruedClinicalTrialLiability
9108000 USD
CY2021Q1 jazz Accrued Interest
AccruedInterest
7539000 USD
CY2020Q4 jazz Accrued Interest
AccruedInterest
5722000 USD
CY2021Q1 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
7304000 USD
CY2020Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
6742000 USD
CY2021Q1 jazz Accrued Collaboration Costs Current
AccruedCollaborationCostsCurrent
4918000 USD
CY2020Q4 jazz Accrued Collaboration Costs Current
AccruedCollaborationCostsCurrent
444000 USD
CY2021Q1 jazz Accrued Construction In Progress
AccruedConstructionInProgress
835000 USD
CY2020Q4 jazz Accrued Construction In Progress
AccruedConstructionInProgress
1119000 USD
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
33999000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
31313000 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
374035000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
352732000 USD
CY2021Q1 us-gaap Long Term Debt
LongTermDebt
2101646000 USD
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
2094838000 USD
CY2021Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
248613000 USD
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
246322000 USD
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1853033000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1848516000 USD
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
243852000 USD
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
33387000 USD
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
517494000 USD
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
575000000 USD
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
0 USD
CY2021Q1 jazz Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
1000000000 USD
CY2021Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
2369733000 USD
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
5546000 USD
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
5290000 USD
CY2021Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1375000 USD
CY2020Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
870000 USD
CY2021Q1 us-gaap Variable Lease Cost
VariableLeaseCost
1000 USD
CY2020Q1 us-gaap Variable Lease Cost
VariableLeaseCost
1000 USD
CY2021Q1 us-gaap Sublease Income
SubleaseIncome
0 USD
CY2020Q1 us-gaap Sublease Income
SubleaseIncome
157000 USD
CY2021Q1 us-gaap Lease Cost
LeaseCost
6922000 USD
CY2020Q1 us-gaap Lease Cost
LeaseCost
6004000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
125738000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
129169000 USD
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
14048000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
14457000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
136020000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
140035000 USD
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
150068000 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
154492000 USD
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y7M6D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y8M12D
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.053
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.053
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
6293000 USD
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
6215000 USD
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
375000 USD
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
201000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
16009000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
22265000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
22352000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
24192000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
18405000 USD
CY2021Q1 jazz Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
86495000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
189718000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
39650000 USD
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
150068000 USD
CY2021Q1 us-gaap Unrecorded Unconditional Purchase Obligation Due In Next Rolling Twelve Months
UnrecordedUnconditionalPurchaseObligationDueInNextRollingTwelveMonths
88800000 USD
CY2021Q1 us-gaap Oci Before Reclassifications Net Of Tax Attributable To Parent
OciBeforeReclassificationsNetOfTaxAttributableToParent
-46236000 USD
CY2021Q1 us-gaap Reclassification From Aoci Current Period Net Of Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
-1160000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-45076000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
121832000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-157833000 USD
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56468000 shares
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55956000 shares
CY2021Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1584000 shares
CY2020Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2021Q1 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
341000 shares
CY2020Q1 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58393000 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55956000 shares
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.16
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.82
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.09
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.82
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
607581000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
534726000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
607581000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
534726000 USD
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
4861000 USD
CY2021Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
636000 USD
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
4225000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
34485000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28654000 USD
CY2021Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
6587000 USD
CY2020Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
3121000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
27898000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
25533000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
18000000.0 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-51300000 USD
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.133
CY2020Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.245
CY2021Q1 jazz Income Tax Examination Penalties And Interest Paid
IncomeTaxExaminationPenaltiesAndInterestPaid
18600000 USD
CY2021Q1 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
1100000 USD

Files In Submission

Name View Source Status
0001232524-21-000031-index-headers.html Edgar Link pending
0001232524-21-000031-index.html Edgar Link pending
0001232524-21-000031.txt Edgar Link pending
0001232524-21-000031-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
jazz-20210331.htm Edgar Link pending
jazz-20210331.xsd Edgar Link pending
jazz-20210331_cal.xml Edgar Link unprocessable
jazz-20210331_def.xml Edgar Link unprocessable
jazz-20210331_htm.xml Edgar Link completed
jazz-20210331_lab.xml Edgar Link unprocessable
jazz-20210331_pre.xml Edgar Link unprocessable
jazzq12021ex311.htm Edgar Link pending
jazzq12021ex312.htm Edgar Link pending
jazzq12021ex321.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending